



**Biocon Limited**  
20th KM, Hosur Road  
Electronic City  
Bangalore 560 100, India  
T 91 80 2808 2808  
F 91 80 2852 3423

CIN : L24234KA1978PLC003417

[www.biocon.com](http://www.biocon.com)

BIO/SECL/SP/2024-25/42

June 15, 2024

|  |   |
|--|---|
| To<br>The Manager,<br><b>BSE Limited</b><br>Department of Corporate Services<br>Phiroze Jeejeebhoy Towers,<br>Dalal Street, Mumbai – 400 001<br><b>Scrip Code - 532523</b> | To<br>The Manager,<br><b>National Stock Exchange of India Limited</b><br>Corporate Communication Department<br>Exchange Plaza, Bandra Kurla Complex<br>Mumbai – 400 050<br><b>Scrip Symbol - Biocon</b> |
|--|---|

**Subject: Notification to Stock Exchanges**

Dear Sir/Madam,

This is to *inform you that “the U.S. Food and Drug Administration (USFDA) concluded a GMP inspection of our API facility (Site 6), located at Visakhapatnam, Andhra Pradesh, on 14 June 2024. Three observations were cited at the end of the Inspection, which we will be addressing within the stipulated time.*

*Biocon stands committed to Quality, Safety & Efficacy of the products manufactured.”*

The above information will also be available on the website of the Company at [www.biocon.com](http://www.biocon.com).

Kindly take the same on record and acknowledge.

Thanking You,

Yours faithfully,

For **Biocon Limited**

---

**Mayank Verma**  
**Company Secretary & Compliance Officer**  
**Membership No: ACS 18776**